Summary and Key Takeaways from FDA’s September 2026 Public Hearing on Psychedelic Drugs
On September 14, 2026, FDA convened a Part 15 hearing to discuss “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.” The meeting was a compilation of 2 minute segments for 80 public commentators representing a diverse community of academia, patients, advocates, service providers, and industry.
The Essential Role of Real World Evidence Combating COVID-19
Are you prepared for potential accelerated approval requirements?
ISPE’s Position on Real World Evidence (RWE)
Read more about the February 2020 position on RWE from ISPE.
Lack of Label Alignment & Patient Safety Implications
Read the full article from UBC’s pharmacovigilance team in Drugs Real World Outcomes.
Risk Management Plan Development & Implementation
Listen to the full podcast from UBC with PharmaVOICE here.
Are You Ready For Sentinel? | New RWE Safety Initiative
With continued investment in the RWE space, find out how to meet the needs of regulators, payers, and prescribers.
Immunogenicity: Meeting the Safety Reporting Requirements
Discover why it is imperative to assess the potential of therapeutic proteins throughout the product lifecycle.
DIA 2019: Watch the Wrap-up of UBC’s Participation
See more of the developments UBC’s evidence development and safety & risk management teams discussed.
Apple’s ResearchKit: The Panacea for Patient Recruitment?
Learn more about this latest offering from Apple and what it could mean for clinical research.
